Neuropediatrics 2018; 49(S 01): S1-S12
DOI: 10.1055/s-0038-1653942
Invited Speakers' Abstracts
Georg Thieme Verlag KG Stuttgart · New York

Lafora Disease: A Perspective in Molecular Mechanism and Pathology

Brandy Verhalen
1   Division of Neurology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, United States
,
Susan Arnold
2   Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas, United States
,
Berge A. Minassian
1   Division of Neurology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, United States
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
27. April 2018 (online)

 
 

    Lafora disease is a neurodegenerative disorder caused by recessive loss-of-function mutations in the EPM2A (laforin glycogen phosphatase) or EPM2B (malin E3 ubiquitin ligase) genes. Neuropathology is characterized by malformed precipitated glycogen aggregates termed Lafora bodies. Asymptomatic until adolescence, patients undergo first insidious then rapid progressive myoclonus epilepsy toward a vegetative state and death within a decade. Laforin and malin interact to regulate glycogen phosphorylation and chain length pattern, the latter critical to glycogen’s solubility. While significant gaps remain in precise mechanistic understanding, therapeutic options appear near, as partial brain glycogen synthesis prevents the disease in its genetic animal models.


    #

    Die Autoren geben an, dass kein Interessenkonflikt besteht.